Top of this page
Skip navigation, go straight to the content

Investors Overview

we aspire to be the patient-preferred biotech leader. 

To achieve this goal, UCB has become an innovation-driven global biopharmaceutical company creating value for patients, the company, its shareholders and society in general.

Our work has an impact on the lives of many people. Every UCB employee is committed to follow the strict regulatory standards for research, development, manufacturing and distribution of our products to ensure we meet all safety, quality, regulatory, legal and environmental requirements.

In an ever-changing and more complex environment, UCB’s patient value strategy is the best route to achieve this ambition and long-term success. 

30 October 2018 
9 month interim report

Business general picture


  • 07.00 CET Press release
  • No conference call

IR events

DateEvent details
20 November
ING Benelux Conference,  Brussels1/1 meetings
22 November
Bryan Garnier Healthcare conference 2018, Paris1/1 meetings
29 November
Roadshow in LondonBroker: Deutsche Bank

Outlook 2018

2018 revenue reporting to reach approximately

€ 4.5-4.6 billion 

Recurring EBITDA [Operating profit adjusted for amortisation, depreciation, impairment charges, restructuring expenses and other exceptional income and expenses.] in the range of

€ 1.3-1.4 billion 

Core earnings per share are therefore expected in the range of

€ 4.30-4.70

based on an average of
188 million shares outstanding

Contact UCB IR team or a specific team member:




UCB IR app available on Apple Store

UCB IR app available on Google Play